A detailed history of Northern Trust Corp transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Northern Trust Corp holds 120,290 shares of DMAC stock, worth $581,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
120,290
Previous 120,389 0.08%
Holding current value
$581,000
Previous $355,000 41.97%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$2.8 - $4.49 $277 - $444
-99 Reduced 0.08%
120,290 $504,000
Q2 2024

Aug 14, 2024

SELL
$2.16 - $3.66 $16,048 - $27,193
-7,430 Reduced 5.81%
120,389 $355,000
Q1 2024

May 14, 2024

SELL
$2.58 - $3.23 $15,000 - $18,779
-5,814 Reduced 4.35%
127,819 $354,000
Q4 2023

Feb 13, 2024

BUY
$2.05 - $2.99 $90,062 - $131,359
43,933 Added 48.98%
133,633 $379,000
Q3 2023

Nov 13, 2023

BUY
$2.56 - $4.4 $19,302 - $33,176
7,540 Added 9.18%
89,700 $231,000
Q2 2023

Aug 11, 2023

SELL
$1.53 - $4.4 $13,257 - $38,126
-8,665 Reduced 9.54%
82,160 $354,000
Q1 2023

May 15, 2023

SELL
$1.32 - $1.89 $2,960 - $4,239
-2,243 Reduced 2.41%
90,825 $138,000
Q4 2022

Feb 13, 2023

BUY
$1.13 - $1.62 $3,179 - $4,558
2,814 Added 3.12%
93,068 $147,000
Q3 2022

Nov 14, 2022

SELL
$1.2 - $2.07 $13,740 - $23,701
-11,450 Reduced 11.26%
90,254 $112,000
Q2 2022

Aug 12, 2022

BUY
$1.86 - $2.62 $3,277 - $4,616
1,762 Added 1.76%
101,704 $206,000
Q1 2022

May 13, 2022

SELL
$2.29 - $3.88 $3,070 - $5,203
-1,341 Reduced 1.32%
99,942 $250,000
Q4 2021

Feb 08, 2022

BUY
$3.43 - $4.65 $53,895 - $73,065
15,713 Added 18.36%
101,283 $378,000
Q3 2021

Nov 15, 2021

BUY
$3.1 - $4.32 $1,162 - $1,620
375 Added 0.44%
85,570 $343,000
Q2 2021

Aug 13, 2021

BUY
$4.45 - $9.91 $752 - $1,674
169 Added 0.2%
85,195 $379,000
Q1 2021

May 12, 2021

SELL
$7.76 - $10.43 $279,072 - $375,094
-35,963 Reduced 29.72%
85,026 $778,000
Q4 2020

Feb 11, 2021

BUY
$4.13 - $10.14 $17,436 - $42,811
4,222 Added 3.62%
120,989 $1.23 Million
Q3 2020

Nov 16, 2020

BUY
$3.91 - $7.15 $81,703 - $149,406
20,896 Added 21.8%
116,767 $495,000
Q2 2020

Aug 14, 2020

BUY
$2.6 - $7.32 $216,855 - $610,531
83,406 Added 669.12%
95,871 $664,000
Q1 2020

May 14, 2020

BUY
$2.25 - $5.64 $28,046 - $70,302
12,465 New
12,465 $35,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $128M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.